截至2025年6月6日收盘，通策医疗(600763)报收于41.95元，下跌0.43%，换手率0.84%，成交量3.77万 手，成交额1.59亿元。 会议审议通过了七项非累积投票议案，包括：1. 2024年年度报告2. 董事会工作报告3. 监事会工作报告4. 2024年度利润分配方案5. 2024年度财务决算报告6. 续聘会计师事务所议案7. 修订公司章程议案 各议案均获得高比例支持，具体表决情况见公告。现金分红分段表决结果显示，持股5%以上和1%-5% 的普通股股东全部同意，持股1%以下普通股股东中89.2999%同意。涉及重大事项时，5%以下股东对利 润分配方案、续聘会计师事务所和修订公司章程议案的支持率分别为97.3250%、97.3024%和 97.1902%。 浙江天册律师事务所朱纯怡律师和李沛雨律师见证了本次股东大会，并认为会议合法有效。 浙江天册律师事务所为通策医疗股份有限公司2024年年度股东大会出具法律意见书，认为本次股东大会 的召集与召开程序、出席会议人员的资格、会议表决程序均符合法律法规和公司章程规定，表决结果合 法有效。 当日关注点 交易信息汇总 6月6日，通策医疗的资金流向显示，主力 ...

Core Viewpoint - Tongce Medical (600763) has shown a positive stock performance, closing at 41.95 CNY, a 1.52% increase from the previous week, with a total market capitalization of 18.764 billion CNY [1] Company Announcements - The 2024 Annual General Meeting of Tongce Medical was successfully held on June 5, 2025, with 595 attendees representing 36.5312% of the voting shares [1] - Seven non-cumulative voting resolutions were approved during the meeting, including the 2024 annual report, board work report, supervisory board work report, profit distribution plan, financial settlement report, reappointment of accounting firm, and amendments to the company’s articles of association [1][3] - The voting results showed high support for all resolutions, with significant backing from shareholders holding more than 5% and 1%-5% of shares, and 89.2999% support from shareholders holding less than 1% [2] Legal Compliance - The meeting was witnessed by lawyers from Zhejiang Tiance Law Firm, confirming that the meeting was legally valid and complied with relevant laws and company regulations [2][3]

Meeting Overview - The shareholders' meeting of Tongce Medical Co., Ltd. was held on June 5, 2025, at the company's headquarters in Hangzhou [1] - The meeting was convened by the board of directors and chaired by Chairwoman Wang Yi, following legal and procedural requirements [1] Voting Results - All proposed resolutions were approved by the shareholders, with significant support from A-shareholders [2][3] - The voting results for the annual report showed 99.7649% approval from A-shareholders, with only 0.1801% against and 0.0550% abstaining [1] - The cash dividend proposal received 99.7415% approval, with 0.1908% against and 0.0677% abstaining [2] Shareholder Participation - The meeting included participation from various shareholder categories, with 100% approval from major shareholders holding over 5% of shares [2] - Among shareholders holding less than 1%, 89.2999% voted in favor of the proposals, indicating strong support from smaller investors [2] Legal Compliance - The meeting was witnessed by lawyers from Zhejiang Tian Ce Law Firm, confirming that the meeting's procedures and voting were in compliance with legal and regulatory standards [3]

Core Viewpoint - The legal opinion letter from Zhejiang Tiance Law Firm confirms the legality and validity of the procedures and results of the annual general meeting of Tongce Medical Co., Ltd. for 2024 [1][2][6] Group 1: Meeting Procedures - The annual general meeting was proposed and convened by the board of directors, with the notice published on May 15, 2025 [2][3] - The meeting utilized a combination of on-site and online voting, with the on-site meeting scheduled for June 5, 2025, at 14:30 [2][3] - The online voting period was set for June 5, 2025, from 9:15 to 15:00 [3] Group 2: Attendance and Voting - Attendees included all registered shareholders from the Shanghai branch, with the option to appoint proxies who do not need to be shareholders [3][4] - A total of 3 individuals attended the meeting in person, representing 159,642,160 shares, approximately 35.6910% of the total share capital [4] - The total number of participants in the voting, including both on-site and online, was 595, representing 163,400,082 shares, approximately 36.5312% of the total share capital [4] Group 3: Voting Results - The voting process adhered to legal and regulatory requirements, with results announced on-site without objections from attendees [6] - The voting results for various proposals showed overwhelming support, with approval rates ranging from 99.7317% to 99.7649% [5][6] - The meeting did not vote on any matters not listed in the notice [6] Group 4: Conclusion - The legal opinion concludes that the meeting's convening, attendance qualifications, and voting procedures complied with relevant laws and regulations, confirming the validity of the voting results [6]

证券代码：600763 证券简称：通策医疗 公告编号：2025-011 通策医疗股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 595 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 163,400,082 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 36.5312 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长王毅女士主持本次股东大会。会议的召 开程序、表决方式等符合《公司法》及《公司章程》的有关规定。本次会议采取 现场结合网络的表决方式。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事7人，出席7人； 有限公司 2024 年年度报告摘要》 2、 ...

法律意见书 浙江天册律师事务所 关于 通策医疗股份有限公司 2024 年年度股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于 通策医疗股份有限公司 2024 年年度股东大会的 法律意见书 编号：TCYJS2025H0805 号 致：通策医疗股份有限公司 浙江天册律师事务所（以下简称"本所"）接受通策医疗股份有限公司（以 下简称"通策医疗"或"公司"）的委托，指派本所律师参加贵公司 2024 年年 度股东大会，并根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）、中国证券监督管理委 员会《上市公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和 其他有关规范性文件的要求出具本法律意见书。 在本法律意见书中，本所律师仅对本次股东大会表决程序及表决结果的合法 有效性发表意见，不对会议所审议的议案内容和该等议案中所表述的事实或数据 的真实性和准确性发表意见。 本法律意见书仅供 2024 年年度股东大会之 ...

Core Insights - Tongce Medical (600763) reported a closing price of 41.32 yuan as of May 30, 2025, reflecting a 0.29% increase from the previous week [1] - The company will hold its 2024 annual shareholders' meeting on June 5, 2025, to discuss various proposals [1][2] Financial Performance - In 2024, the company achieved operating revenue of 2.874 billion yuan, a year-on-year increase of 0.96% [2] - The net profit attributable to shareholders was 501 million yuan, representing a 0.20% year-on-year growth [2] - The company distributed a cash dividend of 4.50 yuan per 10 shares, totaling 201 million yuan, with a cash dividend ratio of 40.14% [2] Operational Highlights - The number of medical institutions under the company increased to 89, with 3,100 dental chairs and an outpatient volume of 3.5334 million visits, up 5.37% year-on-year [2] - The board of directors approved 35 proposals and held 10 meetings, while the supervisory board convened 8 times to oversee financial and operational management [2] Upcoming Events - The annual shareholders' meeting will address the 2024 annual report, profit distribution plan, financial settlement report, and the reappointment of the accounting firm [1][2]

Group 1 - The company will hold its annual shareholders' meeting on June 5, 2025, at 14:30, with both on-site and online voting options available [1][2] - The agenda includes the review and voting on several proposals, including the annual report, profit distribution plan, and financial statements [1][2][3] - The company aims to enhance its operational efficiency and digital transformation while focusing on cost reduction and resource integration [3][12] Group 2 - In 2024, the company achieved a revenue of 2.874 billion yuan, representing a year-on-year growth of 0.96%, and a net profit attributable to shareholders of 501.43 million yuan [3][21] - The company has expanded its dental chair installations to 3,100 and served 3.5334 million outpatient visits, marking a 5.37% increase [3][21] - The company plans to distribute a cash dividend of 4.50 yuan per 10 shares, pending shareholder approval [19][20] Group 3 - The company has outlined a strategic plan for 2025, focusing on customer value, resource optimization, and data-driven operations [12][15] - Key initiatives include the development of AI-driven healthcare solutions, enhancing patient management systems, and improving operational efficiency [13][18] - The company aims to establish a model for future hospitals, integrating advanced technologies and smart healthcare practices [15][17]

通策医疗股份有限公司 2024 年年度股东会资料 通策医疗股份有限公司 2024 年年度股东会 会议资料 通策医疗股份有限公司董事会 2025 年 6 月 5 日 1 通策医疗股份有限公司 2024 年年度股东会资料 通策医疗股份有限公司 2024 年年度股东会会议资料目录 一、程序文件 1. 大会会议议程 《通策医疗股份有限公司 2024 年度财务决算报告》； 二、提交股东会审议表决的议案 议案 1 《通策医疗股份有限公司 2024 年年度报告》和《通策医疗股份有限公司 2024 年年度报告摘要》； 议案 2 《通策医疗股份有限公司 2024 年度董事会工作报告》； 议案 3 《通策医疗股份有限公司 2024 年度利润分配方案》； 议案 4 议案 5 《通策医疗股份有限公司关于续聘会计师事务所的议案》； 议案 6 《通策医疗股份有限公司 2024 年度监事会工作报告》； 议案 7 《通策医疗股份有限公司关于修订<公司章程>的议案》。 35 通策医疗股份有限公司 2024 年年度股东会资料 通策医疗股份有限公司 2024 年年度股东会议程 一、现场会议时间： 2025 年 6 月 5 日（星期四）下午 14 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Tongce Medical, which operates in the dental healthcare sector [1][2] - As of May 16, Tongce Medical's closing price was 40.62 yuan, with a decline of 1.43%, resulting in a rolling PE ratio of 35.47 times and a total market capitalization of 18.169 billion yuan [1] - The average PE ratio for the healthcare services industry is 37.33 times, with a median of 39.22 times, positioning Tongce Medical at 26th place within the industry [1][2] Group 2 - As of the first quarter of 2025, 21 institutions held shares in Tongce Medical, including 18 funds, with a total holding of 209.5898 million shares valued at 9.488 billion yuan [1] - The main business of Tongce Medical includes providing dental healthcare services and research, with key products being medical services, product sales, construction engineering, and comprehensive service fees [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 745 million yuan, a year-on-year increase of 5.11%, and a net profit of 184 million yuan, reflecting a year-on-year growth of 6.22%, with a gross profit margin of 44.21% [1]